An Open-Label, Randomized Phase 3 Study Of Mk-2870 As A Single Agent And In Combination With Pembrolizumab Versus Treatment Of Physician's Choice In Participants With Hr+/Her2- Unresectable Locally Advanced Or Metastatic Breast Cancer
Posted Date: Apr 25, 2024
- Investigator: Amanda Jackson
- Specialties:
- Type of Study: Drug
The purpose of this study is to compare MK-2870 as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
Criteria:
Null
Keywords:
Her2 Negative
For More Information:
Krista Swegheimer
NULL
cancer@uchealth.com